From the Guidelines

The recommended duration of therapy with Lovenox (enoxaparin) is for the duration of hospitalization, up to 8 days.

The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines recommend continuing enoxaparin for the duration of hospitalization, up to 8 days, if given before diagnostic angiography 1.
The 2007 focused update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction also recommends maintenance dosing with enoxaparin for the duration of the index hospitalization, up to 8 days 1.
The dosage of enoxaparin is as follows: for patients less than 75 years of age, an initial 30 mg intravenous bolus is given, followed 15 minutes later by subcutaneous injections of 1.0 mg per kg every 12 hours; for patients at least 75 years of age, the initial intravenous bolus is eliminated and the subcutaneous dose is reduced to 0.75 mg per kg every 12 hours 1.
It is essential to note that the serum creatinine levels and creatinine clearance should be considered when determining the dosage of enoxaparin, and adjustments should be made accordingly 1.

The guidelines emphasize the importance of individualized treatment and clinical judgment in determining the duration and dosage of enoxaparin therapy.
The risk of heparin-induced thrombocytopenia and bleeding should be carefully considered when administering enoxaparin, especially in patients with renal impairment or those who are elderly.

From the Research

The recommended duration of therapy with Lovenox (enoxaparin) varies depending on the patient's condition and the specific indication for use.

For the treatment of venous thromboembolism, the duration of therapy is not explicitly stated in the provided studies, but it is mentioned that enoxaparin can be used for long-term therapy in patients with cancer and renal insufficiency 2.
For the prevention of venous thromboembolism in acutely ill, nonsurgical patients, the optimal duration of prophylaxis is currently being evaluated, but short-term enoxaparin appears to provide a cost-effective treatment alternative to unfractionated heparin 3.
For bridging therapy, enoxaparin can be administered for an average of 19.5 days, with a half-therapeutic dose regimen appearing to be safe and effective in patients with a target INR of 2.0-3.0 and at an intermediate risk of thromboembolic events 4.

The duration of therapy with enoxaparin should be individualized based on the patient's specific needs and risk factors.
The use of enoxaparin in patients with severe renal insufficiency requires careful consideration, as the recommended doses may need to be revisited 2.
Further studies are needed to determine the optimal duration of therapy with enoxaparin in different patient populations, including those with cancer and renal insufficiency 2, 5.